Donanemab for Early Cognitive Decline with Lewy Bodies
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Gradual worsening of thinking or memory lasting at least 6 months
- At least one symptom of dementia with Lewy bodies (such as visual hallucinations, movement problems, or sleep issues)
- Pass a cognitive assessment (MoCA score of 20 or higher)
- Show specific protein markers in blood and spinal fluid indicating brain amyloid and alpha-synuclein pathology
- Have a trusted family member or caregiver willing to participate and help monitor you throughout the study
- Be able to safely undergo MRI and PET brain scans and a spinal tap
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
This trial tests a monthly infusion drug called donanemab, which aims to clear amyloid plaques (a hallmark of Alzheimer's) from the brain, potentially slowing memory decline in people with early Alzheimer's disease. Participants will receive the drug as part of this study.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Hear when a new Cognitive Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.